Detail akcie Danaher Corp online

Business Summary: Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three business segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including deoxyribonucleic acid (DNA)and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Danaher Corp revenues decreased 10% to $23.89B. Net income applicable to common stockholders excluding extraordinary items decreased 32% to $4.2B. Revenues reflect Biotechnology segment decrease of 18% to $7.17B, Diagnostics segment decrease of 12% to $9.58B, United States segment decrease of 15% to $9.58B, All Other segment decrease of 5% to $11.17B.